Health Care • Biotechnology: Pharmaceutical Preparations
$7.31 ▲ +0.00
(0.00%)
MKT CAP: $29.5M • VOL: 4.3K
52W L $5 52W H $13
ROARABLE / RQD
E • 28/100
PIOTROSKI
3 / 9
RMTI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $69.3M | $101.5M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $11.7M | $17.5M | — |
| Gross Margin % | 16.9% | 17.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$4.7M | $608.0K | -$6.7M |
| Operating Margin % | -6.8% | 0.6% | — |
| Net Income (GAAP) | -$5.3M | -$480.0K | -$8.4M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$659.0K | $4.2M | -$9.4M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$659.0K | $4.2M | -$9.4M |
| FCF Margin % | -1.0% | 4.1% | — |
| Return on Invested Capital (ROIC %) | -10.6% | 1.9% | — |
| Cash & Short-Term Equivalents | $10.7M | $15.7M | — |
| Total Debt (Short + Long Term) | $8.8M | $8.5M | — |
| Total Stockholders' Equity | $37.0M | $32.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RMTI.